Sklivanioti Greenfield Myrto, Wang Yanlu, Msghina Mussie
Department of Clinical Neuroscience (CNS), Karolinska Institute, Stockholm, Sweden.
Department of Clinical Science, Intervention, and Technology, Karolinska Institute, Stockholm, Sweden.
Front Psychiatry. 2023 Jan 4;13:988893. doi: 10.3389/fpsyt.2022.988893. eCollection 2022.
Adaptive and successful emotion regulation, the ability to flexibly exert voluntary control over emotional experience and the ensuing behavior, is vital for optimal daily functioning and good mental health. In clinical settings, pharmacological and psychological interventions are widely employed to modify pathological emotion processing and ameliorate its deleterious consequences.
In this study, we investigated the acute effects of single-dose escitalopram on the induction and regulation of fear and disgust in healthy subjects. Furthermore, we compared these pharmacological effects with psychological emotion regulation that utilized a cognitive strategy with reappraisal. Emotion induction and regulation tasks were performed before and 4 h after ingestion of placebo or 10 mg escitalopram in a randomized, double-blind design. The International Affective Picture System (IAPS) was used as a source of images, with threat-related pictures selected for fear and disease and contamination-related pictures for disgust. Behavioral data, electrodermal activity (EDA), and functional near-infrared spectroscopy (fNIRS) recordings were collected.
Escitalopram significantly reduced emotion intensity for both fear and disgust during emotion induction, albeit with differing electrodermal and hemodynamic activity patterns for the two negative emotions. At rest, i.e., in the absence of emotive stimuli, escitalopram increased sympathetic activity during the fear but not during the disgust experiments. For both fear and disgust, emotion regulation with reappraisal was more effective in reducing emotion intensity compared to pharmacological intervention with escitalopram or placebo.
We concluded that emotion regulation with reappraisal and acute administration of escitalopram, but not placebo, reduce emotion intensity for both fear and disgust, with cognitive regulation being significantly more efficient compared to pharmacological regulation under the conditions of this study. Results from the fNIRS and EDA recordings support the concept of differential mechanisms of emotion regulation that could be emotion-specific.
适应性且成功的情绪调节,即灵活地对情绪体验及随之而来的行为施加自主控制的能力,对于日常最佳功能和良好心理健康至关重要。在临床环境中,药物和心理干预被广泛用于改变病理性情绪加工并减轻其有害后果。
在本研究中,我们调查了单剂量艾司西酞普兰对健康受试者恐惧和厌恶情绪的诱发及调节的急性影响。此外,我们将这些药理作用与采用重新评估认知策略的心理情绪调节进行了比较。在随机、双盲设计中,于摄入安慰剂或10毫克艾司西酞普兰之前及之后4小时进行情绪诱发和调节任务。使用国际情感图片系统(IAPS)作为图像来源,选择与威胁相关的图片用于诱发恐惧,选择与疾病和污染相关的图片用于诱发厌恶。收集行为数据、皮肤电活动(EDA)和功能近红外光谱(fNIRS)记录。
艾司西酞普兰在情绪诱发期间显著降低了恐惧和厌恶的情绪强度,尽管两种负面情绪的皮肤电和血流动力学活动模式有所不同。在静息状态下,即在没有情感刺激时,艾司西酞普兰在恐惧实验中增加了交感神经活动,但在厌恶实验中未增加。对于恐惧和厌恶,与使用艾司西酞普兰或安慰剂的药理干预相比,采用重新评估的情绪调节在降低情绪强度方面更有效。
我们得出结论,采用重新评估的情绪调节以及艾司西酞普兰而非安慰剂的急性给药,可降低恐惧和厌恶的情绪强度,在本研究条件下,认知调节比药理调节显著更有效。fNIRS和EDA记录的结果支持情绪调节存在不同机制的概念,这些机制可能具有情绪特异性。